<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01675037</url>
  </required_header>
  <id_info>
    <org_study_id>1122602</org_study_id>
    <secondary_id>2011-A01077-34</secondary_id>
    <nct_id>NCT01675037</nct_id>
  </id_info>
  <brief_title>Hypothalamic-pituitary Effects After Endoscopic Third Ventriculostomy</brief_title>
  <official_title>Hypothalamic-pituitary Effects After Endoscopic Third Ventriculostomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Endoscopic third ventriculostomy (ETV) is a standard procedure for the treatment&#xD;
      of obstructive hydrocephalus in children and adults. Perforation of the third ventricle floor&#xD;
      which is part of the hypothalamic-pituitary neuronal network is the key of this surgical&#xD;
      procedure.&#xD;
&#xD;
      Purpose: There are no prospective data available about the endocrine effects after ETV in&#xD;
      children and adults. The principal aim of this prospective study is to evaluate the&#xD;
      variability of hypothalamic-pituitary hormones and clinical effects in children and adults&#xD;
      after ETV in order to plan a multicentric study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction Endoscopic third ventriculostomy (ETV) is a standard procedure for the treatment&#xD;
      of obstructive hydrocephalus in children and adults. Perforation of the third ventricle floor&#xD;
      which is part of the hypothalamic-pituitary neuronal network is the key of this surgical&#xD;
      procedure. Single patients with endocrine or electrolyte abnormalities after ETV have been&#xD;
      reported in children or adults. So far there are no prospective data available about the&#xD;
      endocrine effects after ETV.&#xD;
&#xD;
      Materials and methods 40 patients (10 children, 30 adults) with obstructive hydrocephalus and&#xD;
      inclusion criteria will undergo ETV in our neurosurgical department. Complete&#xD;
      hypothalamic-pituitary hormonal evaluation will be done, in children and adults, before the&#xD;
      procedure and at 3 and 12 month after ETV. At 3 month, a brain MRI, with&#xD;
      hypothalamic-pituitary specifics sequences, will be performed and compared to the&#xD;
      preoperative one. Follow up will be at 3 and 12 month after ETV.&#xD;
&#xD;
      Interventions: ETV is performed under general anesthesia with a rigid endoscope. Perforation&#xD;
      is made just behind the clivus, halfway between the infundibulum and the mammillary bodies in&#xD;
      the midline using a monopolar electrode, followed by dilatation with an inflated balloon&#xD;
      catheter. In our department, this procedure is performed only by 2 senior surgeons.&#xD;
&#xD;
      Number of subjects: 40 patients: 10 children, 30 adults. Statistical analysis: stratified&#xD;
      analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment failure&#xD;
  </why_stopped>
  <start_date type="Actual">July 2012</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Variability of hypothalamic-pituitary hormones after endoscopic third ventriculostomy</measure>
    <time_frame>12 months</time_frame>
    <description>Complete hypothalamic-pituitary hormonal evaluation</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">11</enrollment>
  <condition>Obstructive Hydrocephalus</condition>
  <arm_group>
    <arm_group_label>obstructive</arm_group_label>
    <description>obstructive hydrocephalus in children and adults with biological evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological evaluation</intervention_name>
    <description>Complete hypothalamic-pituitary hormonal evaluation</description>
    <arm_group_label>obstructive</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, and urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients over 6 months-old with obstructive hydrocephalus who are referred for planned&#xD;
        endoscopic third ventriculocisternostomy to department of neurosurgery in University&#xD;
        Hospital of Toulouse, France.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all patients over 6 months old with obstructive hydrocephalus who are referred for&#xD;
             planned endoscopic third ventriculocisternostomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MRI contraindication, non obstructive hydrocephalus, life expectancy inferior of 3&#xD;
             months, ETV in emergency, hydrocephalus aetiology interaction with&#xD;
             hypothalamic-pituitary hormones, hydrocephalus already treated, basilar artery&#xD;
             malformations, to be allergic to tetracosactide (synacthene) and to benserazide&#xD;
             (Levodopa).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck-Emmanuel Roux, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univesity Hospital Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>August 27, 2012</study_first_submitted>
  <study_first_submitted_qc>August 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2012</study_first_posted>
  <last_update_submitted>March 12, 2017</last_update_submitted>
  <last_update_submitted_qc>March 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypothalamic</keyword>
  <keyword>pituitary,</keyword>
  <keyword>endoscopic third ventriculostomy</keyword>
  <keyword>hydrocephalus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Diseases</mesh_term>
    <mesh_term>Hydrocephalus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

